Alvotech (ALVO) announced that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar
- Alvotech price target lowered to $10 from $13 at UBS
- Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals
- Alvotech Reports Strong Turnaround in Financial Performance
- Alvotech’s Earnings Call: Growth Amid Challenges